Email Updates

You are here

Long-Acting Injectable Cabotegravir

Long-acting injectable PrEP is an experimental strategy based on the drug cabotegravir, an antiviral medication. The study HPTN 083 has shown high levels of protection using cabotegravir as a long acting injectable (CAB-LA) among men who have sex with men and transgender women. Results from a sister study among cisgender women, HPTN 084, are expected in 2022.

Scroll down for resources on CAB-LA research and advocacy.

Understanding the Research Results

Putting the Research in Context